FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment,...